Search Results - "BINLICH, F"

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer by VELTKAMP, S. A, THIJSSEN, B, SCHELLENS, J. H. M, GARRIGUE, J. S, LAMBERT, G, LALLEMAND, F, BINLICH, F, HUITEMA, A. D. R, NUIJEN, B, NOL, A, BEIJNEN, J. H

“…To explore the parmacokinetics, safety and tolerability of paclitaxel after oral administration of SMEOF#3, a novel Self-Microemulsifying Oily Formulation, in…”
Get full text

Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma by San-Miguel, J.F, Hungria, V.T.M, Yoon, S.-S, Beksac, M, Dimopoulos, M.A, Elghandour, A, Jedrzejczak, W.W, Guenther, A, Nakorn, T.N, Siritanaratkul, N, Schlossman, R.L, Hou, J, Moreau, P, Lonial, S, Lee, J.H, Einsele, H, Sopala, M, Redhu, S, Paul, S, Corrado, C, Binlich, F, Richardson, P.G

Get full text

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial by San-Miguel, Jesús F, Prof, Hungria, Vânia T M, MD, Yoon, Sung-Soo, Prof, Beksac, Meral, Prof, Dimopoulos, Meletios Athanasios, Prof, Elghandour, Ashraf, Prof, Jedrzejczak, Wieslaw Wiktor, Prof, Günther, Andreas, MD, Nakorn, Thanyaphong Na, MD, Siritanaratkul, Noppadol, MD, Corradini, Paolo, Prof, Chuncharunee, Suporn, MD, Lee, Je-Jung, Prof, Schlossman, Robert L, MD, Shelekhova, Tatiana, PhD, Yong, Kwee, Prof, Tan, Daryl, MRCP, Numbenjapon, Tontanai, MD, Cavenagh, Jamie D, MD, Hou, Jian, Prof, LeBlanc, Richard, MD, Nahi, Hareth, Prof, Qiu, Lugui, Prof, Salwender, Hans, MD, Pulini, Stefano, MD, Moreau, Philippe, Prof, Warzocha, Krzysztof, Prof, White, Darrell, Prof, Bladé, Joan, MD, Chen, WenMing, Prof, de la Rubia, Javier, Prof, Gimsing, Peter, MD, Lonial, Sagar, Prof, Kaufman, Jonathan L, MD, Ocio, Enrique M, MD, Veskovski, Ljupco, MD, Sohn, Sang Kyun, Prof, Wang, Ming-Chung, MD, Lee, Jae Hoon, Prof, Einsele, Hermann, Prof, Sopala, Monika, PhD, Corrado, Claudia, MD, Bengoudifa, Bourras-Rezki, MS, Binlich, Florence, MD, Richardson, Paul G, Prof

“…Summary Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with…”
Get full text

Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration by Pearson, Andrew D J, Zwaan, C Michel, Kolb, E Anders, Karres, Dominik, Guillot, Julie, Kim, Su Young, Marshall, Lynley, Tasian, Sarah K, Smith, Malcolm, Cooper, Todd, Adamson, Peter C, Barry, Elly, Benettaib, Bouchra, Binlich, Florence, Borgman, Anne, Brivio, Erica, Capdeville, Renaud, Delgado, David, Faller, Douglas, Fogelstrand, Linda, Fraenkel, Paula Goodman, Hasle, Henrik, Heenen, Delphine, Kaspers, Gertjan, Kieran, Mark, Klusmann, Jan-Henning, Lesa, Giovanni, Ligas, Franca, Mappa, Silvia, Mohamed, Hesham, Moore, Andrew, Morris, Joan, Nottage, Kerri, Reinhardt, Dirk, Scobie, Nicole, Simko, Stephen, Winkler, Thomas, Norga, Koen, Reaman, Gregory, Vassal, Gilles

“…The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40%…”
Get full text

Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer by Awada, A., Dirix, L., Beck, J., Luu, T., Dieras, V., Llombart, A., Manso, L., Limentani, S., Binlich, F., Germa, C., Abbas, R., Agrapart, V., Powell, C., Hershman, D.

“…Background: The irreversible pan-ErbB tyrosine kinase inhibitor neratinib (HKI-272) potently blocks downstream signaling of the ErbB1, -2, and -4 receptors and…”
Get full text

Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors by Limentani, S. A., Awada, A., Dirix, L., Beck, J., Dieras, V., Binlich, F., Germa, C., Agrapart, V., Powell, C., Hershman, D.

“…Abstract only e14554 Background: Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor. Preclinical studies have shown synergistic…”
Get full text

A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer by Veltkamp, SA, Thijssen, B, Garrigue, J S, Lambert, G, Lallemand, F, Binlich, F, Huitema, ADR, Nuijen, B, Nol, A, Beijnen, J H, Schellens, JHM

“…To explore the parmacokinetics, safety and tolerability of paclitaxel after oral administration of SMEOF#3, a novel Self-Microemulsifying Oily Formulation, in…”
Get full text